EUCTR2020-003657-30-DK进行中（未招募）1 期
FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate theSafety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in PediatricPatients with RAF-Altered, Recurrent or Progressive Low-Grade Glioma andAdvanced Solid Tumors - FIREFLY-1
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients must be age 6 months to 25 years, inclusive, with:
- •a) Arm 1 (Low-Grade Glioma): A relapsed or progressive low-grade
- •glioma (LGG) with a documented known activating BRAF alteration.
- •b) Arm 2 (Low-Grade Glioma Extension): A relapsed or progressive low-
- •grade glioma with a
- •documented known or expected to be activating BRAF mutation or RAF
- •c) Arm 3 (Advanced Solid Tumor): Locally advanced or metastatic solid
- •tumor with a documented
- •known or expected to be activating RAF fusion.
- •- Patients must have histopathologic verification of malignancy at either
- •original diagnosis or relapse.
- •- Must have received at least one line of prior systemic therapy and have
- •documented evidence of radiographic progression
- •- Patients must have evaluable and/or measurable disease as specified
- •a) Arm 1 (Low-Grade Glioma):Must have at least one measurable lesion.
- •b) Arm 2 (Low-Grade Glioma Extension): Must have evaluable and/or
- •measurable disease
- •c) Arm 3 (Advanced Solid Tumor): Must have at least one measurable
- •- Patients must have Karnofsky (those 16 years and older) or Lansky
- •(those younger than 16 years) performance score of at least 50.
- •For the complete list of the inclusion criteria, please refer to the
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 140
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patient has symptoms of clinical progression without radiographically recurrent or radiographically progressive disease.
- •- Patient has history of any major disease, other than the primary malignancy under study, that might interfere with safe protocol participation
- •- Patient has major surgery within 14 days (2 weeks) prior to C1D1
- •- Patient has clinically significant active cardiovascular disease, or history of myocardial infarction, or deep vein thrombosis/pulmonary embolism within 6 months prior to C1D1
- •- Patient is currently enrolled in any other investigational treatment study. Participation in a concurrent observational or bio-sampling study is allowed.
- •For the complete list of the exclusion criteria, please refer to the protocol.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Study to Test Effects of Using DAY101 in Children with Brain CancerEUCTR2020-003657-30-DEDay One Biopharmaceuticals, Inc. (Day One)140
招募中
1 期
A Phase 2 Study to Test Effects of Using DAY101 in Children with Brain CancerRAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors in pediatric patientsMedDRA version: 21.1Level: PTClassification code: 10065443Term: Malignant glioma Class: 100000004864CTIS2024-510691-20-00Day One Biopharmaceuticals Inc.140
进行中（未招募）
1 期
A Phase 2 Study to Test Effects of Using DAY101 in Children with Brain CancerEUCTR2020-003657-30-NLDay One Biopharmaceuticals, Inc. (Day One)140
招募中
1 期
Anti-CEACAM5 ADC M9140 in Advanced Solid TumorsColorectal CancerJPRN-jRCT2031220313Sasazaki Daisuke5
进行中（未招募）
1 期
Study of pharmacokinetics, activity and safety of ruxolitinib in pediatric patients with grade II-IV acute graft vs. host diseasetreatment naïve aGvHD grades II-IV or steroid-refractory aGvHD grades II-IVMedDRA version: 20.0 Level: LLT Classification code 10064677 Term: Graft versus host disease in intestine System Organ Class: 100000004870MedDRA version: 20.0 Level: LLT Classification code 10075161 Term: Graft versus host disease in GI tract System Organ Class: 100000004870EUCTR2018-000422-55-NLovartis Pharma AG43